Taro Pharmaceutical Industries Accounts Payable

Taro Pharmaceutical Industries's accounts payable stands at $45M as of March 2024. That compares with $68M in the prior-year period — down 34.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Taro Pharmaceutical Industries reported $45M in accounts payable versus $68M a year earlier — a 34.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $68M in the prior-year period — down 34.8% year over year. Sustained growth in accounts payable can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Taro Pharmaceutical Industries's accounts payable evolved across reporting periods, while the comparison chart places TARO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, accounts payable is commonly used to spot outliers. Taro Pharmaceutical Industries's reading of $45M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.